New pharmacotherapy for heart failure with reduced ejection fraction

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol. 2017;33:1342–1433.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2013;62:e147–e239.
   PubMed Web of Science ®Google Scholar
• van Riet EES, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review: prevalence of heart failure and ventricular dysfunction. Eur J Heart Fail. 2016;18:242–252.
   PubMed Web of Science ®Google Scholar
• Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000;2:198–205.
   PubMedGoogle Scholar
• Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:9–20.
   PubMed Web of Science ®Google Scholar
• Muto S. Action of aldosterone on renal collecting tubule cells. Nephrol Hypertens. 1995;4:31–40.
   PubMedGoogle Scholar
• Delcayre C. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol. 2002;34:1577–1584.
   PubMed Web of Science ®Google Scholar
• Squire IB, O’Brien RJ, Demme B, et al. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci. 2004;107:309–316.
   PubMed Web of Science ®Google Scholar
• von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin–angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594–605.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Morant-Talamante N, Lupón J. Neprilysin and natriuretic peptide regulation in heart failure. Curr Heart Fail Rep. 2016;13:151–157.
   PubMedGoogle Scholar
• McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Mullens W, Damman K, Harjola V-P, et al. The use of diuretics in heart failure with congestion - a position statement from the heart failure association of the European society of cardiology: diuretics in heart failure. Eur J Heart Fail. 2019;21:137–155.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the framingham study. Am J Cardiol. 1974;34:29–34.
   PubMed Web of Science ®Google Scholar
• Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 Trial. Circulation. 2019;139:2516–2527.
   PubMed Web of Science ®Google Scholar
• Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528–2536.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). Eur J Heart Fail. 2019;21:665–675.
   PubMed Web of Science ®Google Scholar
• Yurista SR, Silljé HHW, Oberdorf‐Maass SU, et al. Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21:862–873.
   PubMed Web of Science ®Google Scholar
• Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019;62:349–357.
   PubMed Web of Science ®Google Scholar
• Nielsen R, Møller N, Gormsen LC, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139:2129–2141.
   PubMed Web of Science ®Google Scholar
• Cohn JN. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.
   Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Cavero PG, Margulies KB, Winaver J, et al. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 1990;82:196–201.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lancet. 1998;351:1657–1658.
   PubMed Web of Science ®Google Scholar
• Lang CC, Motwani J, Coutie WJ, et al. Influence of candroxatil on plasma brain natriuretic peptide in heart failure. Lancet. 1991;338:255.
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106:920–926.
   PubMed Web of Science ®Google Scholar
• Correia LC, Rassi A Jr. Paradigm-HF: a paradigm shift in heart failure treatment? Arq Bras Cardiol. 2016;106(1):77‐79.
   Web of Science ®Google Scholar
• Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens: initiating sacubitril/valsartan in heart failure. Eur J Heart Fail. 2016;18:1193–1202.
   PubMed Web of Science ®Google Scholar
• Norberg H, Bergdahl E, Lindmark K. Safety and Tolerability of initiating maximum-dose sacubitril-valsartan in patients on target dose renin-angiotensin system inhibitors. Cardiovasc Ther. 2019;2019:1–6.
   Web of Science ®Google Scholar
• Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal pro–B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1085.
   PubMed Web of Science ®Google Scholar
• Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322:1077.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539–548.
   PubMed Web of Science ®Google Scholar
• Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21:998–1007.
   PubMed Web of Science ®Google Scholar
• Khalil P, Kabbach G, Said S, et al. Entresto, a new panacea for heart failure? Cardiovasc Hematol Agents Med Chem. 2018;16:5–11.
   PubMedGoogle Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–1620.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463–1476.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Carbone S, Dixon DL. The CANVAS program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18:64.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
   PubMed Web of Science ®Google Scholar
• Hsia DS, Grove O, Cefalu WT. An update on SGLT2 Inhibitors for the treatment of diabetes mellitus. 2018. p. 12.
   Google Scholar
• Barnsbee L, Barnett AG, Halton K, et al. Chapter 24, Cost-effectiveness. In: Gregory SD, Stevens MC, Fraser JF, editors. Mechanical Circulatory and Respiratory Support [Internet]. Academic Press; 2018 [cited 2020 June 4]. p. 749–772. Available from: http://www.sciencedirect.com/science/article/pii/B9780128104910000242
   Google Scholar
• Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1:666–672.
   PubMed Web of Science ®Google Scholar
• Chakravarty A, Rastogi M, Dhankhar P, et al. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. J Med Econ. 2018;21:497–509.
   PubMed Web of Science ®Google Scholar